- Synta Pharmaceuticals (SNTA) says it's launching its Hsp90-inhibitor Drug Conjugate platform, with the intention of creating a new class of anti-cancer therapies.
- The objective is to create novel drug conjugates that exploit Hsp90 biology to selectively deliver potent anti-cancer payloads to cancer cells.
- The drug developer expects to launch its first investigational new drug in next 18 months.
Synta Pharmaceutical launches its proprietary Small Molecule Hsp90-inhibitor Drug Conjugate platform
Sep 10 2013, 16:27 ET